IDEAYA Biosciences (IDYA) said Thursday it has signed an additional clinical trial collaboration and supply agreement with Gilead Sciences (GILD) to assess the efficacy and safety of IDE397 plus Gilead's Trodelvy in methylthioadenosine phosphorylase-deletion, or MTAP-deletion, non-small cell lung cancer.
The drugmakers will include patients with lung cancer in an ongoing phase 1 trial evaluating the combination regimen in MTAP-deletion urothelial cancer, with clinical updates expected this year, IDEAYA Chief Medical Officer Darrin Beaupre said.
IDEAYA said it is currently enrolling patients in a monotherapy expansion in lung and urothelial cancer and is projecting to begin a combination trial of IDE397 and IDE892 in H2.
Shares of IDEAYA fell 4.1%, while Gilead rose 2.2% in recent trading.
Price: 21.06, Change: -0.89, Percent Change: -4.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.